Does Bone-targeted Therapy Benefit Patients with Metastatic Renal Cell Carcinoma?
Sign Up to like & getrecommendations! Published in 2019 at "Translational Oncology"
DOI: 10.1016/j.tranon.2019.10.009
Abstract: INTRODUCTION: In metastatic renal cell carcinoma (mRCC), the bone is the second most common site of metastasis and is associated with increased morbidity and poorer quality of life. Bone-targeted therapies (BTTs) such as denosumab and… read more here.
Keywords: renal cell; bone targeted; cell carcinoma; bone ... See more keywords